EMA Authorised: Vitrakvi (larotrectinib sulfate) — Bayer AG

View source ↗

Summary

EMA authorised Vitrakvi (larotrectinib sulfate) for abdominal neoplasms with conditional approval; Bayer AG is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Neoplasms

Drugs mentioned

• Vitrakvi (larotrectinib sulfate) (larotrectinib sulfate)

Snippet

Status: Authorised. Therapeutic area: Abdominal Neoplasms. MAH: Bayer AG. Decision date: 09/03/2026. Conditional approval